Together, these results proposed that COL8A1 directly interacting with ITGB1 could activate the PI3K-AKT pathway and promote EMT, thereby leading to CRC resistance to oxaliplatin (Fig. 7T). The gene discussed is COL8A1; the disease is colorectal carcinoma.